Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental compounds to lower intraocular pressure.

S M Podos1, C B Camras, J B Serle

  • 1Department of Ophthalmology, Mount Sinai School of Medicine, New York, New York 10029.

Australian and New Zealand Journal of Ophthalmology
|May 1, 1989
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Netarsudil/latanoprost fixed-dose combination for the treatment of open-angle glaucoma or ocular hypertension.

Drugs of today (Barcelona, Spain : 1998)·2019
Same author

Influence of treatment protocol on the long-term efficacy of argon laser trabeculoplasty.

Journal of glaucoma·2009
Same author

Medical treatment of newly diagnosed open-angle glaucoma.

Journal of glaucoma·2009
Same author

Segmental analysis of computerized optic nerve head imaging.

Journal of glaucoma·2009
Same author

Clinical Applications of alpha2-Adrenergic Agonists in Ophthalmology.

Journal of glaucoma·2009
Same author

Peroxiredoxin 6 delivery attenuates TNF-alpha-and glutamate-induced retinal ganglion cell death by limiting ROS levels and maintaining Ca2+ homeostasis.

Brain research·2008
Same journal

Thomas a'Beckett Travers, 1902-1999.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Bowen's disease of the eyelid in a renal transplant recipient on immunosuppressants.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Linear IgA disease.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Ring keratitis from topical anaesthetic misuse.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Lamellar corneal autograft for corneal perforation.

Australian and New Zealand journal of ophthalmology·2000
Same journal

Preretinal haemorrhages: an unusual manifestation of intravitreal amikacin toxicity.

Australian and New Zealand journal of ophthalmology·2000
See all related articles

New ocular hypotensive agents are needed to effectively lower intraocular pressure (IOP) with fewer side effects. Research in primate models explores novel drug candidates for glaucoma treatment.

Area of Science:

  • Ophthalmology
  • Pharmacology

Background:

  • Current glaucoma treatments necessitate improved efficacy and reduced side effects.
  • Laser-induced glaucoma in primates serves as a valuable model for evaluating new ocular hypotensive agents.

Purpose of the Study:

  • To investigate novel therapeutic agents for lowering intraocular pressure (IOP).
  • To assess the efficacy of various drug classes in preclinical primate models and human studies.

Main Methods:

  • Testing alpha-adrenergic agonists/antagonists, prostaglandin analogs, and modified carbonic anhydrase inhibitors.
  • Utilizing laser-induced glaucoma models in monkeys.
  • Evaluating drug effects on intraocular pressure (IOP) in primate and human subjects.

Main Results:

Related Experiment Videos

  • Para-aminoclonidine (alpha2 agonist) reduced post-laser IOP spikes in humans.
  • Prostaglandin F2 alpha-1-isopropyl ester demonstrated significant IOP reduction in glaucomatous monkey eyes and patients.
  • Topical modified carbonic anhydrase inhibitors lowered IOP in monkey models and hypertensive patients.

Conclusions:

  • Several classes of drugs show promise for lowering IOP.
  • Primate models are effective for evaluating potential glaucoma therapies.
  • Further development is needed for novel ocular hypotensive agents.